Association of Thrombotic Markers With Severity of Pediatric-Onset Systemic Lupus Erythematosus

Sheren Esam Maher1, Ahmed Ragab Abdul-Badia1, Mostafa Ahmed Abu El-Ela2

  • 1Department of Pediatrics, Faculty of Medicine, Minia University, El-Minya, Egypt.

Indian Pediatrics
|July 22, 2023
PubMed

Insights

Thrombomodulin and D-dimer levels are elevated in children with pediatric systemic lupus erythematosus (p-SLE). Higher levels of these thrombotic markers correlate with increased disease activity, aiding in distinguishing severe cases.

Area of Science:

  • Pediatric Rheumatology
  • Hematology
  • Immunology

Background:

  • Pediatric-onset systemic lupus erythematosus (p-SLE) is a chronic autoimmune disease with variable clinical manifestations.
  • Assessing disease activity and identifying predictive markers are crucial for effective management of p-SLE.
  • Thrombotic events can be a serious complication in patients with SLE.

Purpose of the Study:

  • To investigate the relationship between thrombotic markers, specifically thrombomodulin and D-dimer, and disease severity in pediatric-onset systemic lupus erythematosus (p-SLE).
  • To determine if these markers can differentiate between low and moderate-to-high disease activity levels in children with p-SLE.

Main Methods:

  • A cohort of 40 children diagnosed with p-SLE was divided into low activity (laSLE) and moderate-high activity (mhaSLE) groups based on the Systemic Lupus Erythematous Disease Activity Index (SLEDAI).
  • Forty healthy children served as a control group.
  • Serum levels of thrombomodulin and D-dimer were quantified in all participants.

Main Results:

  • Children with p-SLE, across both activity groups, exhibited significantly higher mean thrombomodulin and D-dimer levels compared to healthy controls.
  • The moderate-high activity SLE (mhaSLE) group demonstrated significantly elevated thrombomodulin and D-dimer levels compared to the low activity SLE (laSLE) group.
  • Both thrombomodulin and D-dimer showed significant positive correlations with SLEDAI scores, indicating a link to disease severity.

Conclusions:

  • Thrombomodulin and D-dimer serve as valuable biomarkers for assessing disease activity in p-SLE.
  • These markers effectively distinguish children with severe p-SLE activity from those with milder disease, aiding in clinical stratification.
Abstract

Related Concept Videos

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
38
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
14
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
119
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
13
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
8